AGIO Agios Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGIO

Price (delayed)

$24.825

Market cap

$1.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.8

Enterprise value

$1.38B

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In ...

Highlights
AGIO's net income is up by 43% YoY and by 3.7% QoQ
Agios Pharmaceuticals's EPS has increased by 32% YoY and by 4.3% QoQ
The quick ratio is down by 25% year-on-year and by 22% since the previous quarter
Agios Pharmaceuticals's equity has decreased by 14% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agios.com
Peers: XNCR EXEL BMRN PFE

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
55.74M
Market cap
$1.38B
Enterprise value
$1.38B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.43
Price to sales (P/S)
68.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.39
Earnings
Revenue
$20.15M
EBIT
-$210.05M
EBITDA
-$192.31M
Free cash flow
-$298.88M
Per share
EPS
-$3.8
Free cash flow per share
-$5.38
Book value per share
$17.35
Revenue per share
$0.36
TBVPS
$19.52
Balance sheet
Total assets
$1.09B
Total liabilities
$120.92M
Debt
$78.95M
Equity
$964.24M
Working capital
$702.1M
Liquidity
Debt to equity
0.08
Current ratio
13.73
Quick ratio
12.78
Net debt/EBITDA
0.03
Margins
EBITDA margin
-954.6%
Gross margin
87.1%
Net margin
-1,042.6%
Operating margin
-1,202.6%
Efficiency
Return on assets
-18%
Return on equity
-20.2%
Return on invested capital
-19.4%
Return on capital employed
-20.4%
Return on sales
-1,042.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
1.7%
1 week
-0.98%
1 month
-7.95%
1 year
-10.96%
YTD
-11.59%
QTD
-12.34%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$20.15M
Gross profit
$17.56M
Operating income
-$242.28M
Net income
-$210.05M
Gross margin
87.1%
Net margin
-1,042.6%
The net margin has surged by 82% year-on-year and by 9% since the previous quarter
The operating margin has surged by 80% year-on-year and by 6% since the previous quarter
AGIO's net income is up by 43% YoY and by 3.7% QoQ
Agios Pharmaceuticals's operating income has increased by 37% YoY

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.43
P/S
68.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.39
Agios Pharmaceuticals's EPS has increased by 32% YoY and by 4.3% QoQ
The P/B is 59% below the 5-year quarterly average of 3.4
Agios Pharmaceuticals's equity has decreased by 14% YoY and by 7% QoQ
AGIO's P/S is 34% below its last 4 quarters average of 102.3
The revenue has grown by 6% since the previous quarter

Efficiency

How efficient is Agios Pharmaceuticals business performance
Agios Pharmaceuticals's return on sales has surged by 82% YoY and by 9% QoQ
The company's return on invested capital rose by 35% YoY
The ROA has grown by 32% YoY
AGIO's return on equity is up by 32% year-on-year

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The quick ratio is down by 25% year-on-year and by 22% since the previous quarter
AGIO's current ratio is down by 24% year-on-year and by 22% since the previous quarter
The debt is 92% smaller than the equity
Agios Pharmaceuticals's equity has decreased by 14% YoY and by 7% QoQ
The debt has declined by 13% year-on-year and by 4.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.